Empagliflozin after acute myocardial infarction: Results of the EMPACT-MI Trial #ACC24

Mirvat Alasnag interviews Javed Butler about the results of the EMPACT-MI trial which he presented at the ACC.2024 in Atlanta.
Among patients at increased risk for heart failure after acute MI, treatment with empagliflozin did not lead to a significantly lower risk of first hospitalization for heart failure or death from any cause than placebo. Despite missing its primary endpoint, SGLT-2 inhibitors show potential in heart failure prevention.

More news about the ACC.24 on PCRonline: https://www.pcronline.com/News/Whats-...

• #education
• #interventional_cardiology
• #cardiology
• #cardiovascular
• #interventional_cardiovascular_medecine